Sigyn Therapeutics Inc Financials

SIGY

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Sigyn Therapeutics Inc (SIGY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Sigyn Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.26x

For every $1 of reported earnings, Sigyn Therapeutics Inc generates $0.26 in operating cash flow (-$872K OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$2.5M

YoY-2.7%

Sigyn Therapeutics Inc's EBITDA was -$2.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.7% from the prior year.

Free Cash Flow

N/A

Net Income

-$3.3M

YoY+19.4%

Sigyn Therapeutics Inc reported -$3.3M in net income in fiscal year 2024. This represents an increase of 19.4% from the prior year.

EPS (Diluted)

$-2.51

YoY+33.4%

Sigyn Therapeutics Inc earned $-2.51 per diluted share (EPS) in fiscal year 2024. This represents an increase of 33.4% from the prior year.

Cash & Debt

$12K

YoY+3.9%

5Y CAGR+89.3%

Sigyn Therapeutics Inc held $12K in cash against $2.0M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+24.6%

Sigyn Therapeutics Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 24.6% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

74.9%

YoY-46.6pp

5Y CAGR-337803.1pp

Sigyn Therapeutics Inc's ROE was 74.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 46.6 percentage points from the prior year.

R&D Spending

$773K

YoY-3.1%

Sigyn Therapeutics Inc invested $773K in research and development in fiscal year 2024. This represents a decrease of 3.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SIGY Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	$143K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$36K
Gross Profit	N/A	N/A	N/A	N/A	N/A	$108K
R&D Expenses	$773K-3.1%	$798K+21.4%	$658K-10.4%	$734K+75.0%	$419K	N/A
SG&A Expenses	$1.7M+5.3%	$1.7M+11.3%	$1.5M+16.9%	$1.3M+156.7%	$496K-19.1%	$614K
Operating Income	-$2.5M-2.6%	-$2.5M-14.3%	-$2.1M-6.9%	-$2.0M-119.1%	-$916K-76.9%	-$518K
Interest Expense	N/A	N/A	N/A	$31K-91.0%	$343K+521.7%	$55K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.3M+19.4%	-$4.1M-41.5%	-$2.9M+2.5%	-$3.0M-138.5%	-$1.3M+59.0%	-$3.1M
EPS (Diluted)	$-2.51+33.4%	$-3.77-20.4%	$-3.13	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$30K+296.7%	$7K-15.4%	$9K	N/A	$206K-14.3%	$240K+3.4%	$233K	N/A
SG&A Expenses	$307K-25.5%	$412K-15.4%	$487K	N/A	$565K+73.8%	$325K-9.6%	$360K	N/A
Operating Income	-$387K+17.7%	-$470K+14.0%	-$546K	N/A	-$808K-34.1%	-$603K+4.3%	-$630K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$579K+60.1%	-$1.5M-117.1%	-$669K	N/A	-$1.2M-38.8%	-$862K-13.8%	-$758K	N/A
EPS (Diluted)	$-0.36+60.0%	$-0.90-114.3%	$-0.42	N/A	$-0.94-34.3%	$-0.70-12.9%	$-0.62	N/A

SIGY Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$214K-33.6%	$322K-3.3%	$333K-53.1%	$710K+2.3%	$694K	$0
Current Assets	$21K-82.0%	$118K+67.9%	$70K-82.1%	$393K-41.4%	$670K+13.9%	$589K
Cash & Equivalents	$12K+3.9%	$12K+39.9%	$8K-97.5%	$341K+304.0%	$84K+16780.4%	$500
Inventory	N/A	$50K0.0%	$50K0.0%	$50K-91.5%	$586K-0.4%	$588K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.7M+25.1%	$3.7M+67.0%	$2.2M+129.4%	$975K+63.9%	$595K+65274.0%	$910
Current Liabilities	$4.6M+27.9%	$3.6M+76.1%	$2.0M+179.0%	$734K+23.4%	$595K+65274.0%	$910
Long-Term Debt	$2.0M-19.4%	$2.5M+10.0%	$2.3M	N/A	N/A	N/A
Total Equity	-$4.5M-30.6%	-$3.4M-79.3%	-$1.9M-619.3%	-$265K-366.8%	$99K+10998.8%	-$910
Retained Earnings	-$14.7M-29.5%	-$11.3M-57.6%	-$7.2M-68.7%	-$4.3M-238.2%	-$1.3M-81263.9%	-$2K

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$136K+161.9%	$52K-78.8%	$244K+14.3%	$214K-50.0%	$427K+33.5%	$320K-1.0%	$323K+0.5%	$322K
Current Assets	$86K+4764.8%	$2K-97.4%	$68K+220.5%	$21K-92.1%	$269K+83.8%	$146K+8.9%	$134K+13.9%	$118K
Cash & Equivalents	$86K+18542.9%	$459-96.4%	$13K+6.2%	$12K-92.6%	$165K+207.2%	$54K+63.4%	$33K+180.9%	$12K
Inventory	N/A	N/A	N/A	N/A	$50K0.0%	$50K0.0%	$50K0.0%	$50K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M+10.3%	$5.5M+5.8%	$5.2M+11.1%	$4.7M+7.4%	$4.4M+9.0%	$4.0M-8.1%	$4.3M+16.3%	$3.7M
Current Liabilities	$4.0M-27.3%	$5.5M+6.5%	$5.2M+11.6%	$4.6M+7.9%	$4.3M+9.6%	$3.9M-7.9%	$4.2M+17.4%	$3.6M
Long-Term Debt	$3.5M+42.6%	$2.5M+3.7%	$2.4M+18.8%	$2.0M+1.3%	$2.0M-0.7%	$2.0M-27.8%	$2.8M+11.0%	$2.5M
Total Equity	-$5.9M-8.8%	-$5.4M-10.0%	-$4.9M-10.9%	-$4.5M-13.6%	-$3.9M-6.8%	-$3.7M+8.7%	-$4.0M-17.8%	-$3.4M
Retained Earnings	-$17.4M-3.4%	-$16.8M-9.5%	-$15.4M-4.6%	-$14.7M-3.7%	-$14.2M-9.2%	-$13.0M-7.1%	-$12.1M-6.7%	-$11.3M

SIGY Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$872K+36.9%	-$1.4M+24.4%	-$1.8M-3.2%	-$1.8M-113.8%	-$830K-477.5%	-$144K
Capital Expenditures	N/A	N/A	$860-97.1%	$29K	N/A	N/A
Free Cash Flow	N/A	N/A	-$1.8M-1.5%	-$1.8M	N/A	N/A
Investing Cash Flow	N/A	N/A	-$860+97.1%	-$29K-171.0%	-$11K-110.8%	$100K
Financing Cash Flow	$873K-37.0%	$1.4M-7.5%	$1.5M-27.3%	$2.1M+122.7%	$925K+2421.4%	$37K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$199K-30.8%	-$152K+48.2%	-$294K-1.5%	-$290K-77.2%	-$164K+10.4%	-$183K+22.4%	-$236K-84.2%	-$128K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$284K+103.2%	$140K-52.6%	$295K+114.6%	$138K-50.0%	$275K+35.0%	$204K-20.7%	$257K+242.3%	$75K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SIGY Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	75.1%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-361.4%
Net Margin	N/A	N/A	N/A	N/A	N/A	-2145.3%
Return on Equity	74.9%-46.6pp	121.5%-32.4pp	153.9%-981.7pp	1135.6%+2405.6pp	-1270.0%-339148.0pp	337878.0%
Return on Assets	-1562.9%-274.6pp	-1288.3%-408.2pp	-880.1%-457.1pp	-423.0%-241.5pp	-181.5%	N/A
Current Ratio	0.00-0.0	0.030.0	0.03-0.5	0.54-0.6	1.13-645.7	646.82
Debt-to-Equity	-0.45+0.3	-0.73+0.5	-1.20+2.5	-3.68-9.7	6.00+7.0	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	9.8%-16.9pp	26.7%+13.2pp	13.5%	N/A	30.5%+7.0pp	23.5%+4.6pp	18.9%	N/A
Return on Assets	-426.7%+2377.0pp	-2803.7%-2530.1pp	-273.7%	N/A	-280.0%-10.7pp	-269.4%-34.9pp	-234.5%	N/A
Current Ratio	0.02+0.0	0.00-0.0	0.010.0	0.00-0.1	0.06+0.0	0.040.0	0.030.0	0.03
Debt-to-Equity	-0.60-0.1	-0.46+0.0	-0.49-0.0	-0.45+0.1	-0.51+0.0	-0.55+0.1	-0.69+0.0	-0.73
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

$3.2M

$4.6M

$13.9M

$5.9M

Pharmala Biotech MDXXF

$8.7M

Frequently Asked Questions

Is Sigyn Therapeutics Inc profitable?

No, Sigyn Therapeutics Inc (SIGY) reported a net income of -$3.3M in fiscal year 2024.

What is Sigyn Therapeutics Inc's earnings per share (EPS)?

Sigyn Therapeutics Inc (SIGY) reported diluted earnings per share of $-2.51 for fiscal year 2024. This represents a 33.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Sigyn Therapeutics Inc's EBITDA?

Sigyn Therapeutics Inc (SIGY) had EBITDA of -$2.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Sigyn Therapeutics Inc have?

As of fiscal year 2024, Sigyn Therapeutics Inc (SIGY) had $12K in cash and equivalents against $2.0M in long-term debt.

What is Sigyn Therapeutics Inc's return on equity (ROE)?

Sigyn Therapeutics Inc (SIGY) has a return on equity of 74.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Sigyn Therapeutics Inc's operating cash flow?

Sigyn Therapeutics Inc (SIGY) generated -$872K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Sigyn Therapeutics Inc's total assets?

Sigyn Therapeutics Inc (SIGY) had $214K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Sigyn Therapeutics Inc spend on research and development?

Sigyn Therapeutics Inc (SIGY) invested $773K in research and development during fiscal year 2024.

How many shares does Sigyn Therapeutics Inc have outstanding?

Sigyn Therapeutics Inc (SIGY) had 2M shares outstanding as of fiscal year 2024.

What is Sigyn Therapeutics Inc's current ratio?

Sigyn Therapeutics Inc (SIGY) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Sigyn Therapeutics Inc's debt-to-equity ratio?

Sigyn Therapeutics Inc (SIGY) had a debt-to-equity ratio of -0.45 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sigyn Therapeutics Inc's return on assets (ROA)?

Sigyn Therapeutics Inc (SIGY) had a return on assets of -1562.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Sigyn Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Sigyn Therapeutics Inc (SIGY) had $12K in cash against an annual operating cash burn of $872K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Sigyn Therapeutics Inc's debt-to-equity ratio negative or unusual?

Sigyn Therapeutics Inc (SIGY) has negative shareholder equity of -$4.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Sigyn Therapeutics Inc's Piotroski F-Score?

Sigyn Therapeutics Inc (SIGY) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sigyn Therapeutics Inc's earnings high quality?

Sigyn Therapeutics Inc (SIGY) has an earnings quality ratio of 0.26x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.